EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chaperonin‐containing TCP1 subunit 6A inhibition via TRIM21‐mediated K48‐linked ubiquitination suppresses triple‐negative breast cancer progression through the AKT signalling pathway

Mengdi Yang, Jianing Cao, Tiantian Liu, Bin Li, Jinyan Wang, Shuangyue Pan, Duancheng Guo, Zhonghua Tao, Xichun Hu iD

Clinical and Translational Medicine · 2024

DOI: 10.1002/ctm2.70097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2024. Verfasst von Mengdi Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Urologic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ubiquitination, Proto-Oncogene Proteins c-akt, Chaperonin Containing TCP-1. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program, FUSCC-Physician Excellence Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Triple‐negative breast cancer (TNBC) is distinguished by a significant likelihood of distant recurrence and an unfavourable prognosis. However, the underlying molecules and mechanisms have not been fully elucidated.

Methods

We investigated the expression profile and clinical relevance of chaperonin‐containing TCP1 subunit 6A (CCT6A) in TNBC. We performed cell function assays on TNBC cells with CCT6A knockdown or overexpression. To further explore the mechanism of action of CCT6A, RNA sequencing and co‐immunoprecipitation–mass spectrometry analyses were utilized. Rescue and ubiquitination assays evaluated the impact of TRIM21‐mediated CCT6A ubiquitination and degradation on TNBC progression in vitro and in vivo. Finally, we studied the potential of Ipatasertib, a pharmacological AKT inhibitor, and/or anti‐PD1 therapy in inhibiting TNBC progression.

Results

Elevated CCT6A expression in TNBC patients was associated with an adverse prognosis and lymph node metastasis. Mechanistically, CCT6A facilitated cell migration, invasion, epithelial‐mesenchymal transition and proliferation by activating the phosphatidylinositol 3‐kinase (PI3K)/AKT pathway. The TRIM21 RING domain is an E3 ligase, facilitating the K48‐linked ubiquitination‐mediated degradation of CCT6A, thereby impeding TNBC progression. Moreover, in the tumour tissues of the CCT6A‐overexpressing mice, the quantity of CD8+ T cells and the concentration of secreted interferon‐gamma were decreased, whereas in the group double‐overexpression of CCT6A and TRIM21, they were elevated; the opposite was observed in the knockdown and double‐knockdown groups. Ipatasertib demonstrated enhanced efficacy in inhibiting cell proliferation, invasion and migration in TNBC cells ectopically expressing CCT6A. When Ipatasertib and anti‐PD1 therapies were combined, both the tumour volume and mass exhibited a notable reduction, while the expression of CD45+CD8+ T cells increased, and that of CD45+CD4+CTLA4+ and CD45+CD4+PD1+ T cells decreased.

Conclusions

Our findings indicate that TRIM21 inhibits TNBC progression by facilitating the K48‐linked ubiquitination‐mediated degradation of CCT6A via the PI3K/AKT signalling pathway. This highlights the potential of Ipatasertib and/or anti‐PD1 as therapeutic strategies, particularly for TNBC patients overexpressing CCT6A. Key points Chaperonin TCP1 subunit 6A (CCT6A) plays an oncogenic role in triple‐negative breast cancer (TNBC) through the AKT signaling pathway. TRIM21 facilitated K48‐linked ubiquitination‐mediated degradation of CCT6A, thereby impeding TNBC progression. Our study collectively underscores the potential of Ipatasertib in conjunction with anti‐PD1 therapy as a promising strategy to counteract CCT6A/AKT hyperactivity‐driven TNBC progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsUbiquitinationProto-Oncogene Proteins c-aktChaperonin Containing TCP-1RibonucleoproteinsSignal TransductionHumansFemaleAnimalsDisease ProgressionMiceCell Line, TumorCell ProliferationSS-A Antigen

Stichwörter der Autor:innen

CCT6ATRIM21immunotherapytriple‐negative breast cancer

Substanzen

Proto-Oncogene Proteins c-aktChaperonin Containing TCP-1RibonucleoproteinsSS-A Antigen

Autor:innen und Institutionen

  • Department of Breast and Urologic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
  • Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P. R. China.

ORCID-Profile: Xichun Hu

Förderung

  • National Natural Science Foundation of China
  • Shanghai Sailing Program
  • FUSCC-Physician Excellence Program
  • Shanghai Anticancer Association SOAR PROJECT
  • Clinical Research Plan of Shanghai Hospital Development Center
  • National Science and Technology Major Project
  • Program for Shanghai Outstanding Academic Leader

Zitieren

APA

Yang, M., Cao, J., Liu, T., Li, B., Wang, J., Pan, S., Guo, D., Tao, Z., & Hu, X. (2024). Chaperonin‐containing TCP1 subunit 6A inhibition via TRIM21‐mediated K48‐linked ubiquitination suppresses triple‐negative breast cancer progression through the AKT signalling pathway. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70097

Vancouver

Yang M, Cao J, Liu T, Li B, Wang J, Pan S, et al. Chaperonin‐containing TCP1 subunit 6A inhibition via TRIM21‐mediated K48‐linked ubiquitination suppresses triple‐negative breast cancer progression through the AKT signalling pathway. Clinical and Translational Medicine. 2024. doi:10.1002/ctm2.70097

BibTeX
@article{Yang2024,
  author = {Yang, Mengdi and Cao, Jianing and Liu, Tiantian and Li, Bin and Wang, Jinyan and Pan, Shuangyue and Guo, Duancheng and Tao, Zhonghua and Hu, Xichun},
  title = {Chaperonin‐containing TCP1 subunit 6A inhibition via TRIM21‐mediated K48‐linked ubiquitination suppresses triple‐negative breast cancer progression through the AKT signalling pathway},
  journal = {Clinical and Translational Medicine},
  year = {2024},
  doi = {10.1002/ctm2.70097}
}
Kostenlos starten →